Germany Liver Cancer Therapeutics Market Analysis

Germany Liver Cancer Therapeutics Market Analysis


$ 3999

By 2030, it is anticipated that the Germany Liver Cancer Therapeutics market will reach a value of $346.8 Mn from $107.2 Mn in 2022, growing at a CAGR of 15.6% during 2022-30. Liver Cancer Therapeutics in Germany is dominated by a few domestic pharmaceutical companies such as Bayer AG, Merck KGaA and Affimed. The Liver Cancer Therapeutics market in Germany is segmented into different types of cancer and different therapy type. Some of the major factors affecting the German Liver Cancer Therapeutics market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.

ID: IN10DEPH039 CATEGORY: Pharmaceuticals GEOGRAPHY: Germany AUTHOR: Dr. Vishwa Modhia

Buy Now

Germany Liver Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Germany Liver Cancer Therapeutics market will reach a value of $346.8 Mn from $107.2 Mn in 2022, growing at a CAGR of 15.6% during 2022-30.

Germany is a high-income, developed country located in the heart of Western Europe. According to the most recent WHO data, 8,057 people died from liver cancer in Germany in 2020, accounting for 1.15 % of all deaths. With an age-adjusted death rate of 4.03 per 100,000 inhabitants, Germany ranks 129th in the world.

Liver cancer, also known as hepatocellular carcinoma (HCC), is a major health concern in Germany, where it is the sixth most frequent type of cancer. The development and availability of therapies for liver cancer are critical in the prevention and treatment of this disease. In Germany, several medicines are utilised to treat liver cancer. Sorafenib (Nexavar), an oral medicine that inhibits the growth of cancer cells and has been demonstrated to enhance survival in people with advanced liver cancer, is one of the most regularly utilised therapies. In Germany, other targeted treatments, such as Lenvatinib (Lenvima) and Regorafenib (Stivarga), are used to treat liver cancer. Germany's government spends 12.8 % of its GDP on healthcare.

Germany Liver Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

Several advancements in liver cancer therapies have occurred in Germany in recent years. The advent of targeted medicines such as sorafenib and lenvatinib, which have been found to be effective in treating advanced HCC, has been one of the important growth reasons. Furthermore, progress has been made in the development of immunotherapies for liver cancer, with medications like nivolumab and pembrolizumab showing promise in clinical trials. Germany has a low structural unemployment rate and an extensive apprenticeship programme. These aspects could boost the German Liver Cancer Therapeutics market.

Market Restraints

In comparison to other countries of the world, Germany has a low incidence of liver cancer. As a result, clinical trial patient populations may be constrained, slowing the development and approval of new medicines. Despite immigration, the labour force is predicted to shrink beginning in 2020. These factors may deter new entrants into the German Liver Cancer Therapeutics market.

Competitive Landscape

Key Players

  • Bayer AG - Bayer AG is a German multinational pharmaceutical company that develops and produces a range of medicines, including treatments for liver cancer such as sorafenib (Nexavar) and regorafenib (Stivarga)
  • Merck KGaA - Merck KGaA is a German multinational pharmaceutical company that develops and produces a range of medicines, including treatments for liver cancer such as pembrolizumab (Keytruda)
  • Affimed GmbH - Affimed GmbH is a German biopharmaceutical company that develops immuno-oncology therapies for the treatment of a range of cancers, including liver cancer. The company's lead drug candidate, AFM13, is currently in clinical trials for the treatment of liver cancer
  • SIRION Biotech GmbH - SIRION Biotech GmbH is a German biotechnology company that develops viral vector technologies for the delivery of gene therapies for the treatment of a range of diseases, including liver cancer
  • apceth Biopharma GmbH

Healthcare Policies and Reimbursement Scenarios

In Germany, the regulation of liver cancer therapeutics is overseen by the Federal Institute for Drugs and Medical Devices (BfArM). Regarding reimbursement, Germany has a comprehensive public healthcare system that provides coverage for its citizens and residents. The healthcare system is managed by the statutory health insurance (SHI) system and is based on the principle of mandatory health insurance.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

  • Hepatocellular Carcinoma
  • Cholangio Carcinoma
  • Hepatoblastoma
  • Other Types

By Treatment (Revenue, USD Billion):

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Radiation Therapy
  • Ablation Therapy
  • Embolization Therapy

By Equipment (Revenue, USD Billion):

  • Computed Radiography
  • MRI
  • Sonography
  • Others

By Route of Administration (Revenue, USD Billion):

  • Oral
  • Intravenous

By End User (Revenue, USD Billion):

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.

In Germany, the regulation of liver cancer therapeutics is overseen by the Federal Institute for Drugs and Medical Devices (BfArM).

The healthcare system is managed by the statutory health insurance (SHI) system and is based on the principle of mandatory health insurance in Germany.

The Liver Cancer Therapeutics in Germany is dominated by a few domestic pharmaceutical companies such as Bayer AG, Merck KGaA and Affimed.


Last updated on: 08 December 2023
Updated by: Dhruv Joshi

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up